Clinical Trial Search

Primary: Dose Limiting Toxicities (DLT) - Number of Participants With at Least 1 DLT — 0; 0; 0; 0 Participants

Primary: Leg Blood Flow as Measured by Doppler Ultrasound — 174.99; 102.08; 428.45 ml/minute

Primary: Rectal Epithelial Cell Proliferation — 19.3; 20.3; 18.9; 16.8 percentage of cells positive

Primary: Mean Change in 24 Post Dose Trough Forced Expiratory Volume in 1 Second (FEV1) — 0.0477; 0.1009; 0.0648; 0.0632 liters — p=0.0003

Primary: Determine the Objective Tumor Response Rate Following Treatment With TKI258 — 2; 22; 10 Participants

Primary: Percentage of Patients With a 2 Year Disease-Free Survival (DFS) as a Measure of Efficacy — 56; 83; 73 percentage of patients

Primary: Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All…

Primary: Change in Maximum Keratometry From Baseline to 6 Months After Treatment — 0.76; 0.97 diopters

Primary: Primary Cohort: Overall Survival (OS) Censored at 138 Deaths (ITT Set) — 3.8; 5.4; 4.6 months

Primary: Progression-free Survival (PFS) in Patients With AJCC Stage IV Metastatic Melanoma Treated With Docetaxel and Vinorelbine as First-line or Post-first Line (Salvage)…

Primary: Number of Subjects With Solicited Local Symptoms, Overall — 127; 60; 4; 0 Participants

Primary: Improved Vision — 0.67; 0.55; 0.53 logMAR

Primary: Change in Hepatic Fat — -10.046; 3.083; -4.013 percentage — p=0.0572

Primary: Progression-Free Survival — 2.64; 1.38 months

Primary: Time to Progression (TTP)